Demy-Colton的动态

How much do you think was the valuation of the single-cell multi-omics market in Europe alone in 2023? $350 million How much is it expected to be worth by 2033 though? $??.???? ?????????????? According to a report from BIS Research, this takes into account the growing interest in personalized medicine and usage of a multi-omic approach in drug development. What does this mean for us here in Cambridge? As the biotech hub of the country with new spin-offs and start-ups innovating in the space every month, we can hopefully look forward to more rounds of funding and real investment into innovation and scientific development. Have you seen any promising start-ups that you expect will be the next big thing? Curious to know more about what the start-up life is like? Let's connect to talk about all things Omic! #omics #cambridge #startuplife

?? Exciting Collaboration Alert! ?? Integrated Biosciences, Inc. and Illumina Ventures Labs are teaming up to revolutionize the world of novel therapeutics by targeting the transcriptome! ??? This innovative partnership aims to leverage cutting-edge technologies to develop groundbreaking treatments and advance healthcare. ?? By focusing on the transcriptome, they are opening new doors in precision medicine and bringing us closer to personalised therapies. This collaboration signifies a major step forward in the biotech industry, promising innovative solutions for complex diseases. ?? Stay tuned for more updates as these two powerhouses drive forward the future of therapeutic development! #Biotech #HealthcareInnovation #PrecisionMedicine #Transcriptome #NovelTherapeutics #IntegratedBiosciences #IlluminaVentures #LifeSciences #MedicalBreakthroughs ????

We’re just days away from #BioFuture2024, and we couldn’t be more excited to welcome the innovators who are shaping the future of #healthcare! From public, private, and seed companies to those pioneering #TechBio and breakthrough therapeutics, we’re thrilled to showcase the diverse range of trailblazing organizations presenting this year. Presenting companies include leaders in biomanufacturing, drug discovery, AI, and other rapidly evolving sectors, such as: ?? AiM Medical Robotics? ?? iBio, Inc.? ?? AtlasXomics Inc.? ?? Cytonus Therapeutics ?? Glucotrack? ?? Hervolution Therapeutics? ?? OncoRx Insights? …and so many more! This year’s BioFuture promises to be an unparalleled experience to connect with these visionary companies, learn about their latest breakthroughs, and explore future opportunities. From personalized medicine to digital health and AI-driven innovations, our presenting companies are at the forefront of shaping the next era of healthcare solutions. If you're a biotech leader, venture capitalist, strategic partner, or part of the media—this is your opportunity to register now, secure your seat, and join 600+ global attendees in New York City at Cure., October 28-30.? ?? Register now: https://lnkd.in/eHyYaywS ? ??? Presenting companies: https://lnkd.in/eBBUXmG4 ? ? #Biotech #Biopharma #AI #DigitalHealth #DrugDevelopment #Therapeutics #TechBio #ResearchAndDevelopment #Innovation #VC #VCFunding #Partnering #BiotechLeaders #DemyColton?

Do you know who is leading AMR research today? ? 93% of clinical R&D is lead by small companies ? 86.7% of preclinical R&D too! Small companies and biotech are at the forefront of antibacterial development. However, these small teams receive less public and private funding compared to other scientific sectors, resulting in a fragile pipeline. ?? Read more here: https://lnkd.in/dU4Gnxb7 Tamarie Rocke #WHO Antibacterial Pipeline analysis

Had a great time chatting with Elliot and Anastasia, and a big thanks to BlueYard Capital for suggesting the idea. At Zafrens, we're doing foundational work that encapsulates a lot of possibilities even in the few things we do. I had the opportunity to talk about our immunotherapy work in this discussion, and will look forward to sharing more nuances over time. https://lnkd.in/gnQpz5Wd [For the broader context - the function of a cell is dictated by the levels and/or sequences of various molecules it contains. It's been hard to measure the molecules in a cell and simultaneously study what they make the cell do (or, equivalently, predict how the molecules reconfigure if the cells is disturbed by drugs, and its consequences on the cell). Most of our progress in biology has come from charting this ome-to-function map in small, tiny increments - by altering levels or sequence of one molecule at a time, for instance. But even a 10 base sequence of DNA can exist in ~1 million forms, so studying cells at low throughput only tells us so much. Zafrens unleashes our ability to map lots, and lots of molecular changes to each of their individual functional effects. The implications of this touches all of biology, because once you have dense maps of 'cause-and-effect', we can start predicting (and engineering) desired cell states and cell behavior more accurately. Could this help predict if a molecule will work for a patient? We think so. Rather than empirically observing physiological responses and cell-functional responses, we feel understanding how the collection of molecules inside a cell respond could give us more predictive information. That is what we are excited to prove to ourselves, but along the way we are eager to unlock lots of other transformative opportunities with our high-throughput, high-resolution peek into biology].

Last month we asked - what aspect of preclinical research do you find most challenging? ?? The majority answered... Data analysis. Data analysis can be one of the most overwhelming aspects of preclinical research, but it doesn’t have to be. How We Can Help: ?? Expert Analysis: Our team of scientists uses advanced methodologies to interpret your data with precision. ?? Customized Solutions: We tailor our data analysis to fit your specific research needs, ensuring relevance and accuracy. ?? Clear Reporting: We provide comprehensive reports that help you understand and utilize your findings. With our expertise and cutting-edge technologies, we deliver accurate and reliable results to advance your scientific endeavors. #laboratory #preclinical #datanalysis #drugdevelopment #therapeutics #oncologyresearch #research

Experience the dynamic fusion of innovation, impact, and professional growth in preclinical research?? Discover why this field could be your next big leap forward and let us pave the way to your success: https://buff.ly/3Kyjysy #PreclinicalResearch #Innovation #CareerGrowth

?? Sanofi x AQEMIA: Redefining the way new medicines are developed, atom by atom??? Together,?we aim to redefine the way new medicines are developed,?accelerating the delivery of innovative treatments to patients. By combining?Sanofi’s R&D expertise?with?AQEMIA’s physics-powered algorithms, our partnership is pioneering the design and optimization of molecules with unparalleled speed and precision. In this conversation,?Matt Truppo?(Sanofi’s Global Head of Research Platforms & Computational R&D) and?Maximilien Levesque?(AQEMIA CEO & Cofounder) discuss how this unique collaboration is?accelerating progress in drug discovery. Watch the full discussion below?? #Biotech #GenAI #DrugDiscovery

Harvard engineers are unleashing the potential of data science to supercharge drug discovery. ???? By analyzing vast datasets and identifying potential drug candidates with unprecedented precision, the advanced technologies can be employed to streamline the drug discovery process, optimizing the identification of novel therapeutic solutions. What implications might this Harvard-led initiative have on the healthcare landscape? #HarvardInnovation #DataScience #DrugDiscovery #HealthTech #Innovation # https://hubs.la/Q02g_-tK0

Three simple steps to success for any biotech company CEO: 1. prioritize patients 2. innovate quickly 3. stay motivated I asked Sam Clark, MD PhD, CEO of Terran Biosciences, what guides all his work. His response was short and to the point. "Focus on our key stakeholder: the patient. It is that motivation that allows us to overcome the IP barriers set up by other companies and bring these new medications to patients, these potential prodrugs with improved pharmacokinetics." Watch the full interview here: https://lnkd.in/edSgVVi4